Standards

Editorial Policy

Diabetes Magna Plus™ produces educational content for patients exploring treatment pathways for type 2 diabetes and metabolic disease. This policy describes how content is researched, written, sourced, reviewed, and updated.

Last medically reviewed: June 1, 2026 · Educational content only — not medical advice.

Purpose

Help patients make informed healthcare decisions in partnership with qualified clinicians. We do not provide medical advice, diagnosis, or treatment recommendations.

Sourcing

Content is grounded in:

  • Society guidelines (ASMBS, IFSO, ADA, AACE).
  • Regulatory documentation (FDA, EMA, manufacturer IFUs).
  • Peer-reviewed clinical trials and meta-analyses.
  • Government and academic sources (NIH/NIDDK).
  • Documented program-level outcomes from the OCC experience.

Accuracy

Statements about device authorization, procedures, medications, outcomes, and risks are intended to reflect the current evidence at the time of last review. If you identify an inaccuracy, please contact us at info@obesitycontrolcenter.com.

Neutrality and disclosure

  • We do not claim that any treatment is a cure for type 2 diabetes.
  • We do not guarantee specific outcomes.
  • We do not disparage other evidence-based treatments, including GLP-1 therapy.
  • We disclose that Diabetes Magna Plus™ is affiliated with Obesity Control Center (OCC), an active bariatric and metabolic surgery program.

Review cycle

Content is reviewed at least every six months, or sooner when major guideline or regulatory updates occur. Each page displays the date last reviewed.

Corrections

Substantive corrections are recorded in the page's review log. Minor copy edits do not trigger a new review date.

AI-assisted drafting

Some drafts may be prepared with assistance from generative AI tools. All medical content is reviewed by a qualified clinician prior to publication. AI is not used to generate medical advice, diagnose, or determine candidacy.